EUS-FNA predicts 5-year survival in pancreatic endocrine tumors

Endoscopic ultrasound consists of a flexible endoscope which has a small ultrasound device built into the end. The ultrasound component produces sound waves that create visual images of the digestive tract which extend beyond the inner surface lining. EUS can be used to evaluate an abnormality below the surface such as a growth that was detected at a prior endoscopy or by X-ray. EUS can also be used to diagnose diseases of the pancreas, bile duct, and gallbladder when other tests are inconclusive, and can be used to determine the stage of cancers. Tissue samples, using a fine needle aspiration technique (FNA), can be obtained in real time with EUS guidance should an abnormality be seen.

Pancreatic endocrine tumors (PETs) are tumors from the abnormal growth of pancreatic cells that produce hormone-like chemicals and differ in clinical behavior and prognosis than the more common type of pancreatic cancer of the pancreas glands (adenocarcinoma). Determination of malignant (cancerous) potential through specimens obtained by EUS-FNA can help in the management of these patients. Researchers at the Institute Paoli-Calmettes, Marseilles, France, set out to determine the value of EUS-FNA for the diagnosis of PETs and for classifying the underlying malignant potential of these tumors based on the proposed World Health Organization (WHO) classification. Although EUS-FNA is often used for diagnosing PET, there are no data on its accuracy in determining the malignant potential of PETs and in applying the WHO classification. This single-center, retrospective cohort study, the largest experience of EUS-FNA in the diagnosis of PET, involved 86 patients who had been diagnosed with PETs and submitted to EUS-FNA from January 1999 to August 2008.

source: American Society for Gastrointestinal Endoscopy